Cracking the Code: How Patient Navigation Can Revolutionize Hepatitis C Care
"Discover how a targeted approach to patient care is transforming outcomes for those most in need."
Hepatitis C virus (HCV) silently infects millions, yet a cure is within reach. However, many individuals, particularly those facing socioeconomic challenges, struggle to access and complete the necessary treatment. This disparity highlights a critical gap in our healthcare system.
Groundbreaking research from the New York City Department of Health and Mental Hygiene is shedding light on a promising solution: patient navigation. Their "Check Hep C" program demonstrates how targeted support can dramatically improve treatment rates and outcomes for high-need patients.
This article will explore the key findings of the Check Hep C program, revealing how patient navigation addresses barriers to care, improves treatment adherence, and ultimately helps more people achieve a cure. Discover how this model could be a game-changer in the fight against hepatitis C.
Tracking Hepatitis C’s Impact
CDC’s HepTracker dashboard lets users view hepatitis C case-surveillance and viral-hepatitis-related mortality data, which can help inform public-health programs and monitor progress toward eliminating viral hepatitis as a public-health threat in the United States. WHO’s Global Health Observatory provides access to health statistics for its 194 Member States, including an indicator for the number of people who initiated hepatitis C treatment. Since 2014, chronic hepatitis C has been treatable with 8–12 weeks of oral therapy, and WHO’s 2015 elimination targets included treatment goals for member countries. The supplied sources describe where surveillance and treatment data can be found but do not provide a current U.S. case or mortality total.
The Check Hep C Model: A Bridge to Better Outcomes
The Check Hep C program focused on providing intensive support to patients diagnosed with chronic HCV, particularly those facing challenges like homelessness, substance use, or mental health issues. The program's core strategy was patient navigation (PN), a system designed to guide individuals through the complexities of the healthcare system.
- Risk assessment
- Health education
- Treatment readiness counseling
- Medication adherence support
- Medication coordination
Navigation and Integrated HCV Care
A narrative review on integrating diagnosis of hepatitis B, C, and D viruses and HIV in populations evaluated for sexually transmitted infections presents an operational framework that includes navigator-assisted referral and peer support for people with prior healthcare disengagement. It also describes decentralized treatment delivery, including telemedicine and care based in primary-care, prison, or addiction-service settings. In the Seek, Test, and Rapid Treatment randomized trial among young people who inject drugs, usual-care participants were referred to an onsite HCV patient navigator within the syringe services program before HCV RNA test results were available; the navigator was funded through New York City’s Check Hep C program. A Greater New Orleans patient-perspectives study also reports optimism, gratitude for treatment, achieving care milestones, and wanting to get healthy as facilitators of engagement in care.
When HCV Treatment Needs Retreatment
Direct-acting antiviral (DAA) treatment does not succeed for everyone: one review reports initial cure rates of 95%–99% and retreatment cure rates of 95%, while noting that some people will experience multiple DAA failures. Another review describes virological failure as occurring in a small proportion of people treated with DAAs and examines retreatment in a large real-world cohort. For treatment failure, pan-genotypic regimens are recommended as first-line and rescue treatments; when they are unavailable, the cited review lists using different DAA classes, extending treatment duration, adding ribavirin, and testing for resistance-associated substitutions as general retreatment principles. These sources show that failure can require a tailored retreatment strategy, even though cure rates are high.
A Path Forward: Scaling Up Patient Navigation for Hepatitis C
The Check Hep C program provides compelling evidence that patient navigation is a powerful tool for improving hepatitis C care, especially among vulnerable populations. By addressing the unique barriers faced by these individuals, we can significantly increase treatment rates and achieve better outcomes.
Care Pathways and the Elimination Goal
A systematic review and meta-analysis examined treatment uptake, treatment completion, and sustained virologic response among adults receiving DAA-only regimens through community- and primary-care-based pathways. The review included studies using observational and experimental designs, focusing on whether these care settings support the treatment cascade. A 2025 review notes that untreated HCV can progress through fibrosis to cirrhosis complications and end-stage liver disease over 3–4 decades. An expert opinion published in 2026 states that modern DAA regimens cure more than 95% across most populations, while identifying underserved populations, simplified diagnostic pathways, equitable treatment and retreatment access, and harm-reduction investment as priorities for eliminating HCV as a public-health threat.
Closing the Gap to 2030
WHO’s Global hepatitis report 2026 says viral hepatitis remains a leading global health problem despite available prevention and treatment tools. It reports that a 12-week antiviral treatment for hepatitis C has been available since 2015 and has a 95% cure rate, and frames progress toward the 2030 global targets as an ongoing challenge. A 2024 review of acute hepatitis C focuses on risk factors, natural history, therapeutic management, and future perspectives. The supplied description says its approach is supported by a cost-effectiveness analysis but does not specify the analysis’s results.
The Stakes of Timely Treatment
CDC notes that some people may get better without treatment, but waiting can put them at risk of future health problems. Untreated chronic hepatitis C can cause severe liver damage, liver cancer, and death. A 2024 review estimates that approximately 50 million people were living with chronic hepatitis C globally, based on WHO figures, and describes HCV as a significant global health challenge. The review also says direct-acting antiviral regimens have significantly improved treatment, offering potentially high cure rates.
While the study highlights the success of on-site clinical care, it also underscores the importance of adapting patient navigation strategies to different settings. Further research is needed to optimize these models and ensure their effectiveness across diverse communities.
Ultimately, the widespread adoption of patient navigation programs could be a game-changer in the fight against hepatitis C. By investing in these services, we can move closer to eliminating this disease and improving the health and well-being of countless individuals.